Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VABOR-KIDS paediatric Vaborem safety, tolerability, and pharmacokinetics study
2024-514656-32-00Phase 2Authorised
- Sponsor
- Menarini Group
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of meropenem + vaborbactam in Gram-negative bacterial infection and complicated urinary tract infection (cUTI), sponsored by Menarini Group. Primary endpoint: Individual pharmacokinetic parameters. Planned start Jan 2025; status: authorised.
02
Drugs
meropenem + vaborbactam
03
Conditions
Gram-negative bacterial infectioncomplicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on 2024-514656-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514656-32-00.